BLU:NSD-BELLUS Health Inc. (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 9.10

Change

-0.03 (-0.33)%

Market Cap

USD 1.16B

Volume

0.14M

Avg Analyst Target

USD 18.50 (+103.30%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

BLU Stock Forecast & Price:
Based on the BELLUS Health Inc. stock forecasts from 3 analysts, the average analyst target price for BELLUS Health Inc. is USD 18.50 over the next 12 months. BELLUS Health Inc.’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of BELLUS Health Inc. is Bearish, which is based on 2 positive signals and 7 negative signals. At the last closing, BELLUS Health Inc.’s stock price was USD 9.10. BELLUS Health Inc.’s stock price has changed by -0.11% over the past week, -3.09% over the past month and +56.63% over the last year.

About BELLUS Health Inc. (BLU:NSD)

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Ph ...Read More

Company Website : https://www.bellushealth.com

Address : 275 Armand-Frappier Boulevard, Laval, QC, Canada, H7V 4A7

Employees : 40

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : -0.61

52 Week High : 12.69

Short Ratio : 22.65

52 Week Low : 4.98

Shorted Shares : 11,405,895

200 Day Moving Average : 8.87

Shorted Shares Previous Month : 11,428,607

50 Day Moving Average : 9.64

Shares Held By Insiders : 9.56%

Short Percentage : 4.79%

Shares Held by Institutions : 88.37%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-11-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
GILD Gilead Sciences Inc

+0.84 (+0.98%)

 USD106.90B 32.28 22.67
VRTX Vertex Pharmaceuticals Inc

-3.18 (-1.01%)

 USD82.52B 24.98 17.08
REGN Regeneron Pharmaceuticals Inc

+0.87 (+0.12%)

 USD81.59B 15.59 11.88
MRNA Moderna Inc

-0.41 (-0.23%)

 USD68.99B 3.18 4.44
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BNTX BioNTech SE

-1.38 (-0.88%)

 USD37.91B 3.79 1.71
GMAB Genmab AS

+0.34 (+0.77%)

 USD29.03B 36.52 3.47
ALNY Alnylam Pharmaceuticals Inc

+4.23 (+2.03%)

 USD25.76B N/A -27.59
SGEN Seagen Inc

-0.52 (-0.42%)

 USD23.02B 55.02 -41.49
ARGX argenx NV ADR

-2.93 (-0.78%)

 USD20.68B N/A -20.30

ETFs Containing BLU

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.04% 89% B+ 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.04% 89% B+ 91% A-
Trailing 12 Months  
Capital Gain 66.67% 96% A 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 66.67% 96% A 98% A+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 32.11% 84% B 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 32.11% 84% B 87% B+
Risk Return Profile  
Volatility (Standard Deviation) 86.09% 22% F 14% F
Risk Adjusted Return 37.30% 85% B 75% C
Market Capitalization 1.16B 86% B 78% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 97% A+ 98% A+
Price/Book Ratio 2.86 35% F 29% F
Price / Cash Flow Ratio -18.90 89% B+ 75% C
EV/EBITDA -11.01 92% A- 83% B
Management Effectiveness  
Return on Equity -28.91% 81% B- 39% F
Return on Invested Capital -33.29% 69% D+ 30% F
Return on Assets -16.72% 79% C+ 29% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 22.65 6% F 3% F
Short Percent 4.79% 41% F 32% F
Beta -0.61 98% A+ 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment
Stock Target Advisor

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector